Collaborative effort to address intestinal worms through education, medical care, health assessments, quizzes/contests in school
The effectiveness of motivating locals to address intestinal worms through education, medical care and health assessments.
Assessing treatment needs for school-aged children and assisting Ministry of Health to develop an effective control programme
Understanding the basic pharmacology of praziquantel tailored to paediatric setting and developing a treatment access plan for this age class
Helping increase and sustain the scale-up of preventive chemotherapy campaigns in West and Central Africa
TakeUp: Testing the Impact of Incentives on Compliance with Community-based Mass Deworming through a Field Experiment in Kenya
•What is the influence of social and behavioural incentives on the increase in cost-effective demand for deworming medication among adult population?
•What is the impact of social incentives on take-up and cost-effectiveness of deworming treatment?
•What is the impact of consumption incentives on take-up and cost-effectiveness deworming treatment?
•Can any increase in takeup be attributed to signaling effect wherein individuals are motivated to access treatment in order to demonstrate that they have engaged in pro-social behavior?
Community-wide Surveys for Evaluation of LF transmission Interruption, Oncho Transmission Assessment and Comparison of Diagnostic Tools in LF-Onchocerciasis Areas
Assess the performance of LF and Oncho diagnostic tools after stopping LF MDA but continuing Oncho MDA.
Determine whether school-based TAS results in the same programmatic conclusion as a community-based TAS in EUs where school attendance is poor.
Preliminary Findings and Lessons Learned
This USAID project represents an innovative approach to resolve critical questions about the performance of the TAS and in particular, the question of how important 75% school attendance is to a valid TAS result. At its core, this study addresses the concern that LF (specifically antigenemia) could be associated with school attendance, which leads to the programmatic research question: does a school-based TAS result in the same programmatic conclusion as a community-based TAS in EUs where school attendance is poor? This study will lead to a better understanding of the validity of the TAS in programmatic settings where school attendance and/or reporting of school enrollment may be poor. It will also generate important results for the Haitian program that is looking to the TAS for guidance on stopping MDA in several EUs. The school- and community-based TAS were both conducted in a commune considered to be highly endemic (‘zone rouge’) at baseline. Both surveys passed the TAS, with only 1 ICT positive child identified in the school TAS and 4 ICT-positive children in the community-based TAS. The conclusion is that there appears to be no meaningful difference between school- and community-based TAS for stopping MDA decisions, even where school attendance is poor. This is the third LFSC/NTDSC study to return a null result -- perhaps it can now be considered a "non-issue" for LF.
Feasibility, acceptability and cost implications of utilizing the SD BIOLINE Onchocerciasis IgG4 rapid test for onchocerciasis surveillance activities in Senegal
The demonstration study of the SD BIOLINE Onchocerciasis IgG4 rapid test aims to provide operational research data on the use and implementation of the test. The performance of the SD BIOLINE Onchocerciasis IgG4 rapid test has been verified in both reference laboratories as well as in controlled field settings. PATH and partners will explore the feasibility of incorporating the test into multiple sites in sub-Saharan Africa, with Senegal as a pilot country.
We aim to demonstrate the acceptability and feasibility of the SD BIOLINE Onchocerciasis IgG4 test in the Senegal Onchocerciasis Control Programme surveillance activities relative to the diagnostic and collection tools currently used.
To pilot a rapid coverage supervision tool (now known as the Supervisor's Coverage Tool) that can be used to determine if the supervision areas under investigation are likely to have exceeded the WHO threshold for coverage and to serve as an in-process monitoring tool for supervising the MDA distribution. Report to WHO M&E working group; potential for inclusion in future WHO program assessment guidelines.
The Supervisor’s Coverage Tool (SCT) is a quick, simple, and inexpensive monitoring tool that can be used to assess preventive chemotherapy coverage of a mass drug administration (MDA). During the development and optimization process of the tool, the SCT was piloted in communities in Nigeria and Ethiopia. The pilot study in Cross River State, Nigeria, included seven first-level Supervision Areas (SA), which corresponded to villages in four Local Government Areas (LGAs). Drug coverage was assessed for ivermectin and albendazole in four SAs and only Ivermectin in three SAs.
Findings and lessons learned:
- The main reasons for not swallowing medicines were community drug distributor (CDD) not showing up, respondent being away at time of drug distribution or not collecting drug from a fixed point of distribution, fear of side effects, drug supply running out, recent migration, and lack of awareness about drug distribution.
- The SCT permitted LGA coordinators to supervise the drug distribution systematically, which allowed them to find out that in most parts of one LGA treatment was suspended despite the CDD claiming the completion of treatment in the area.
- Some treatment registers did not include all people living in the SA, therefore some households were not included in the CDDs treatment boundaries. On the other hand, some LGAs had very good treatment registers, proper documentation of treatment from CDDs, and their community also commended them during village gatherings expressing their gratitude.
- All CDDs were making remarkable effort with little or no reward. Unlike previous monitoring visits where supervisors have to field numerous complaints around incentives, because the SCT gave supervisors an objective evaluation of their work, many CDDs did not feel justified in complaining about incentives.
- Overall, the SCT was deemed feasible to implement at the supervisory area and the information generated led to programmatic action to improve treatment coverage.